Exhibit 99.1
Eocene
and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol
| ● | A
unique proprietary lipid nanoparticles (LNPs) novel formulation of Aramchol has been developed
using FDA-approved Lipids. |
| ● | The
novel formulation is designed to redirect Aramchol’s biodistribution to target tumor
microenvironment (TME) in liver and GI tumors and selectively inhibit the activity of cells
that drive fibrosis. |
| ● | By
selectively targeting TME cells that drive fibrosis, the Aramchol LNP treatment could make
immunotherapy and other standard of care liver and GI cancer therapies, work better for more
patients with minimal toxicity. |
Givatayim,
Israel, November 16, 2026 – Eocene Ltd. (NASDAQ: EOCN) (“Eocene” or the “Company”) report today updates
from its wholly owned subsidiary, Galmed Research & Development Ltd. (“Galmed”), ongoing collaborative research with
Barcode Nanotech (“Barcode”). Based on Barcode’s proprietary tumor targeting delivery LNPs formulation platform, a
novel Aramchol LNPs formulation was developed. The new LNP formulation aims to redirect Aramchol’s biodistribution to target tumor
microenvironment (TME) in liver and GI tumors.
The
TME is a complex network of immune cells, blood vessels and fibroblasts that interacts with cancer cells to facilitate tumor growth progression
and hamper therapy responsiveness. While current cancer therapies such as immune checkpoint Inhibitors (Keytruda, Opdivo) and angiogenesis
inhibitors (Avastin- anti-VEGF) address immune cells and blood vessels formation in TME, the Company is not aware of any approved therapy
that targets fibrosis to remodel the TME.
As
previously announced, in a randomized, double-blind, placebo-controlled phase IIb trial (ARREST) and an open label extension of a phase
III study (ARMOR), orally formulated Aramchol demonstrated improvement in liver fibrosis in patients with NASH/MASH.
By
employing the Barcode’s existing tumor-targeting LNP formulation, Galmed aims to enhance and accelerate the antifibrotic effect
observed with the oral formulation by redirecting Aramchol’s biodistribution to target tumor microenvironment (TME).
Allen
Baharaff, President and Chief Executive Officer of Eocene commented: “Liver and other cancers often arise in fibrotic tissue as
a result of chronic disease. Fibrosis creates an environment that suppresses immune cells and protects the tumor from the immune system
and immunotherapy. Immunotherapy can initially elicit significant therapy responses which diminish for many patients, and we believe
the fibrotic barrier is a key contributor. We believe Aramchol’s novel LNP treatment could potentially make immunotherapy and other
standard of care for liver and GI cancer therapies, work better for more patients for longer time and better results.”
Ronen
Eavri Chief Executive Officer of Barcode-Nanotech commented: “Building on our earlier work with Galmed to deliver Aramchol to the
brain and the heart, we are now applying our proprietary lipid library and in vivo, AI-based screening platform, including our tumor-targeting
LNP technology, to the development of an Aramchol LNP formulation directed to the tumor microenvironment of liver and GI cancers. By
selectively reaching the cells that drive fibrosis, we hope to help immunotherapy and other standard-of-care treatments work for more
patients.”
About
Eocene (formerly Galmed Pharmaceuticals)
Eocene
Ltd. (NASDAQ: EOCN) is a GI-focused medtech and biopharmaceutical company headquartered in Givatayim, Israel, dedicated to advancing
innovative solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. The Company is building a
diversified platform that combines medical devices, therapeutics and enabling technologies to address significant unmet clinical needs
and improve patient outcomes. Eocene’s wholly owned subsidiary, Galmed Research & Development develop Aramchol, a first-in-class
synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal
cancers. Eocene’s wholly owned medtech subsidiary Colospan Ltd., is a commercial-stage medical device company developing solutions
designed to transform postoperative colorectal care. Its flagship product, CG-100, is an intraluminal bypass device intended to protect
colorectal anastomoses and reduce the need for diverting stomas, offering a less invasive alternative to current surgical practice. CG-100
has received FDA Breakthrough Device Designation, is CE marked under the European Union Medical Device Regulation and is approved for
investigational use in the United States under an FDA-approved IDE. The device is not approved for commercial use in the United States.
About
Barcode Nanotech Ltd.:
Barcode
Nanotech develops delivery solutions for RNA & DNA therapies through a unique multiplexed discovery platform. The Company’s
proprietary NeoRNA™ Targeting Technology enables efficient discovery and optimization of lipid-based nanoparticles (LNPs) through
in silico & in vivo mass-screening. The solution combines the design of thousands of new lipids and LNPs, advanced AI tools and in
vivo barcoding-based biodistribution analysis at a single cell resolution. Using this platform, Barcode has developed unique LNPs that
can direct RNA and other therapies to tumors and to cells in the brain, kidney, lungs and additional target organs. Barcode has an in-house
lead drug development program and concurrently collaborates with biopharma companies to develop new therapies.
For
more information, visit www.eocn.com and www.barcode-nano.com
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our
actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements
may include, but are not limited to, statements relating to: the design, potential benefits and therapeutic potential of the Aramchol
LNP formulation, including its potential to redirect Aramchol’s biodistribution to the tumor microenvironment, inhibit cells that
drive fibrosis and enhance the effectiveness of immunotherapy and other standard-of-care therapies for liver and GI cancers; the progress,
timing and results of preclinical research and any future clinical development of the Aramchol LNP formulation; the continuation and
success of the collaboration between Galmed and Barcode Nanotech; the potential evaluation of Aramchol in oncology indications; the potential
benefits of CG-100 and the progress and results of Colospan’s ongoing U.S. pivotal study of CG-100; the timing, extent and potential
generation of future revenues; the expected benefits arising from the acquisition of Colospan; the Company’s ability to execute
its strategy and growth initiatives, including using its existing capital resources; and the Company’s future business, operations,
financial condition, prospects and objectives. Many factors could cause our actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements, including, but not limited to, the risk that preclinical results may
not be predictive of results in humans; the risk that the Aramchol LNP formulation may not achieve its intended biodistribution, safety
or efficacy, or may not advance into clinical development; the risk that the collaboration with Barcode Nanotech may be delayed, modified
or terminated; our inability to recognize the anticipated benefits of the acquisition of Colospan; expectations with respect to future
performance and growth of Colospan; the development and approval of the use of Aramchol or any other product candidate for indications
outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis
or in combination therapy; the timing and cost of any pre-clinical or clinical trials of CG-100, Aramchol or any other medical device
or product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action
with respect to CG-100, Aramchol or any other medical device or product candidate by the U.S. Food and Drug Administration, or the FDA,
or the European Medicines Agency, or EMA, including but not limited to acceptance of an application for marketing authorization, review
and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future
sales of CG-100, Aramchol and any future medical devices or product candidates; our ability to comply with all applicable post-market
regulatory requirements for CG-100, Aramchol, or any other medical device or product candidate in the countries in which we seek to market
the product; our ability to achieve favorable pricing for CG-100, Aramchol, or any medical device or other product candidate; third-party
payor reimbursement for CG-100, Aramchol, or any other medical device or product candidate; our estimates regarding anticipated capital
requirements and our needs for additional financing; market adoption of CG-100 Aramchol or any other medical device or product candidate
by physicians and patients; the timing, cost or other aspects of the commercial launch of CG-100, Aramchol or any other medical device
or product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may
face third-party claims of intellectual property infringement; our ability to manufacture our CG-100 or product candidates in commercial
quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels;
intense competition in our industry, with competitors having substantially greater financial, technological, research and development,
regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding
licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments
with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The
Nasdaq Capital Market; and the security, political and economic instability in the Middle East that could harm our business, including
due to the current security situation in Israel. We believe these forward-looking statements are reasonable; however, these statements
are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s
actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking
statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC
on March 31, 2026 in greater detail under the heading “Risk Factors” and the additional risk factors relating to the business
of Colospan Ltd. in the section entitled “Risk Factors” in our Report on Form 6-K filed with the SEC on June 8, 2026. Given
these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements
attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by
the cautionary statements included in this press release. We undertake no obligations to update or revise forward-looking statements
to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required
by law. In evaluating forward-looking statements, you should consider these risks and uncertainties.
Investor
and Media contact: +972-3-693-8448, investor.relations@eocn.com